"Death by a Thousand Cuts"

"Death by a Thousand Cuts"

Lingchi, or "death by a thousand cuts," was a historical form of execution practiced in parts of Southeast Asia. This method involved methodically removing small portions of the body with a knife over time, leading to eventual death. In a metaphorical sense, the term has come to describe the gradual destruction of something—such as a business—through a series of small, seemingly minor problems that accumulate over time to catastrophic effect. But what happens when this concept is applied to public policy? Could slow decision-making and incremental missteps lead to a similar fate for institutions or nations?

Let’s take European healthcare legislation as an example

Cast your mind back to 2020: the world was in the midst of a pandemic, Joe Biden had just been elected into office, the Tokyo summer Olympics were postponed, and many discovered the joys of working from home—wearing pyjama bottoms all week, dressing in work attire only from the waist up. Fast forward to now: the pandemic has ended, Biden is no longer in office, we've had the Tokyo and the Paris summer Olympics, and working from home is, quite frankly, not all it’s cracked up to be

Yet, amidst all these changes, one thing has not moved forward that much: the eagerly anticipated EU pharmaceutical legislation. This legislation, part of the European Commission’s Pharmaceutical Strategy for Europe, was unveiled in November 2020 as part of that strategy, with the goal of boosting Europe's competitiveness and improving healthcare outcomes. Originally expected to be completed by 2023, it now won’t be fully adopted until late 2025, or even 2026. That's right—2026. Then we have the period of implementation. That is a long time

When you consider that Beijing Daxing International Airport in China was completed in under five years, the contrast with European projects is striking. Then again, the nearly 14-year construction saga of Berlin Brandenburg Airport suggests that such delays might simply reflect the European norm—a modern day metaphor for the continent's struggles with inefficiency and inertia

So how did we get here?

The delays stem from several key factors:

  • The complexity of the proposals, which aim to balance innovation incentives, drug accessibility, medicine shortages, and new environmental and safety standards
  • Constant wrangling between EU member states who have vested and conflicting interests
  • The need for consultation with a wide range of stakeholders—pharmaceutical companies, regulatory bodies, patient advocacy groups, and member states
  • And of course, the usual back-and-forth between the European Commission, Parliament, and the Council on contentious issues such as market exclusivity, rare disease treatments, and the environmental impact of pharmaceutical production

Needless to say, consensus has been hard to come by, and we all get that. But, whichever way you look at this, it ain’t good

A pressing urgency for a new approach

The "Draghi Report," authored by Mario Draghi (former Prime Minister of Italy and ex-President of the European Central Bank), published in September 2024, critiques the EU’s declining global competitiveness. It argues that reversing this trend will require not just financial investment but also sweeping policy coordination and regulatory reforms. Central to these reforms is reducing bureaucratic obstacles and fostering stronger collaboration between EU member states

The emphasis on cutting red tape and enhancing unity across Europe is a crucial takeaway here. As the US and China continue to solidify their dominance without let up, Europe must act decisively to remain relevant. Faced with long-term decline and rising political volatility at home, European institutions should feel an urgent need to streamline legislation and implement reforms—or risk an irreversible erosion of influence, a "death by a thousand cuts."

要查看或添加评论,请登录

Carsten Edwards的更多文章

  • Save Money, Skip the Gym: Eat Better and Lose Weight

    Save Money, Skip the Gym: Eat Better and Lose Weight

    Just as you cannot save your way to prosperity, it seems that you can't exercise yourself thin. According to this…

    9 条评论
  • How to become a Lion and the Price of Roaring

    How to become a Lion and the Price of Roaring

    A Question of Exhaustion As Christmas draws near and families from all corners of the globe prepare to converge in a…

    1 条评论
  • The Brits Are Coming… Or Are They?

    The Brits Are Coming… Or Are They?

    It's Christmas time and the parties are coming thick and fast. At this time of the year it gets to be fun and…

    27 条评论
  • The Obesity Paradox: Love handles and Longevity

    The Obesity Paradox: Love handles and Longevity

    We’ve all heard it a million times: eat well, exercise, lose weight—because thin is good and fat, any fat, is..

    5 条评论
  • ISPOR – Sunshine, Sangria and Systematic Reviews

    ISPOR – Sunshine, Sangria and Systematic Reviews

    This week, the leading minds of the pharmaceutical world gather to delve into the intricacies of health economics and…

    2 条评论
  • Look at my Shoes

    Look at my Shoes

    Once, while washing my hands in the men's loo at work (that's British for toilet or restroom if you are from the…

    1 条评论
  • GLP-1 Drugs: Between Hype, Hope, and a little Dose of Caution

    GLP-1 Drugs: Between Hype, Hope, and a little Dose of Caution

    In 1987, Dr Joel Habener and his team at Harvard Medical School identified GLP-1, a hormone produced in the gut that…

  • Espresso Machines and Microwave Cookers: In Defence of the Specialist

    Espresso Machines and Microwave Cookers: In Defence of the Specialist

    I always enjoy this debate, especially when it’s applied to pharmaceuticals and biotech. In our business should we…

  • PICO Ahoy!

    PICO Ahoy!

    Both agencies and pharmaceutical companies appear to be raising the alarm to general quarters, largely due to the…

    1 条评论
  • The Costs of Slimming Down

    The Costs of Slimming Down

    Given the impressive data on GLP-1 medications—highlighting both significant weight loss and meaningful clinical…

    2 条评论

社区洞察

其他会员也浏览了